Overview
- CoSara, the joint venture of Co-Diagnostics and ASE Group, signed an agreement adding Bangladesh, Pakistan, Nepal, and Sri Lanka to its commercial and distribution territory.
- Co-Diagnostics estimates the expanded South Asia opportunity at about $13.0 billion based on internal analyses and third-party data.
- The expansion is intended to support future commercialization of the CoSara PCR Pro point-of-care instrument and SARAGENE tests, which require approvals in each market.
- CoSara is building regional channels by assessing regulatory pathways, identifying priority customers, engaging distributors, and scheduling a virtual session in Q2 2026 followed by in-person training this summer.
- Executives described the move as part of a broader infrastructure-first strategy, and Benzinga reported CODX shares rose about 9% in premarket trading following the announcement.